■亚太地区(APAC)代表了生物医学研究出版的独特环境,特别是行业资助的研究。亚太地区对道德出版实践国际准则的认识和采用不断提高,但是,与2015年发布的GPP3相比,2022年良好出版实践(3GPP)指南中的许多建议的重组和扩展对于该地区出版行业资助的生物医学研究具有重要意义.
■本手稿为亚太地区的利益相关者提供了有关解释和应用GPP2022指南中提出的建议的实用指导。
■重点关注领域包括导航新的机会,以沟通行业资助的研究,例如简单的语言摘要,社交媒体,和预印本;实施正式流程以提高亚太地区已发表研究的完整性;以及在出版行业资助的研究时促进透明度和包容性的方法。亚太地区特定的关键问题,包括再来演示,在该地区出版道德方面的领导,获取专业资源,还讨论了对教育区域利益相关者的支持。
■总的来说,该手稿为行业赞助的研究中的利益相关者提供了务实的指南,该研究涉及在亚太地区的背景下有效整合这些指南。
The Asia-Pacific region (APAC) represents a unique environment for the publication of biomedical research, particularly industry-funded research. Awareness and adoption of international
guidelines on ethical publication practices continues to increase across APAC, but the reframing and expansion of many of the recommendations in the Good Publication Practice (GPP) 2022
guidelines versus GPP3 published in 2015 have important implications for publishing industry-funded biomedical research in the region.
This manuscript provides practical guidance for stakeholders in APAC on interpreting and applying the recommendations made in the GPP 2022
guidelines.
Key focus areas include navigating new opportunities for communicating industry-funded research, such as plain language summaries, social media, and preprints; implementing formal processes to improve the integrity of published research in APAC; and methods of promoting transparency and inclusion when publishing industry-funded research. Key APAC-specific issues, including encore presentations, leadership on publication ethics in the region, access to professional resources, and support for educating regional stakeholders are also discussed.
Overall, this manuscript offers a pragmatic guide for stakeholders in industry-sponsored research on applying GPP 2022 in practice with a focus on effectively integrating these
guidelines in an APAC context.